Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$207.3 million.

  • Kymera Therapeutics' Free Cash Flow rose 45.42% to -$27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.2 million, marking a year-over-year decrease of 55.34%. This contributed to the annual value of -$207.3 million for FY2024, which is 51.01% down from last year.
  • Kymera Therapeutics' Free Cash Flow amounted to -$207.3 million in FY2024, which was down 51.01% from -$137.3 million recorded in FY2023.
  • Kymera Therapeutics' Free Cash Flow's 5-year high stood at $79.0 million during FY2020, with a 5-year trough of -$207.3 million in FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$155.9 million (2022), whereas its average is -$166.9 million.
  • Per our database at Business Quant, Kymera Therapeutics' Free Cash Flow spiked by 354.92% in 2020 and then plummeted by 265.17% in 2021.
  • Over the past 5 years, Kymera Therapeutics' Free Cash Flow (Yearly) stood at $79.0 million in 2020, then plummeted by 265.17% to -$130.5 million in 2021, then decreased by 19.44% to -$155.9 million in 2022, then climbed by 11.94% to -$137.3 million in 2023, then tumbled by 51.01% to -$207.3 million in 2024.